Evidence map›Paper›PMID 27127173›Full record

ArticleOncotarget2016

Cytoplasmic, full length and novel cleaved variant, TBLR1 reduces apoptosis in prostate cancer under androgen deprivation.

Garrett Daniels, Xinmin Zhang, Xuelin Zhong, Larion Santiago, Ling Hang Wang, Xinyu Wu, Jack Y Zhang, Fengxia Liang, Xin Li, Thomas A Neubert and 6 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Garrett DanielsDepartment of Pathology, New York University School of Medicine, New York, NY, USA.
Xinmin ZhangDepartment of Pathology and Laboratory Medicine, Hofstra North Shore-LIJ School of Medicine, Hempstead, NY, USA.
Xuelin ZhongDepartment of Pathology, New York University School of Medicine, New York, NY, USA.
Larion SantiagoDepartment of Pathology, New York University School of Medicine, New York, NY, USA.
Ling Hang WangDepartment of Pathology, New York University School of Medicine, New York, NY, USA.
Xinyu WuDepartment of Pathology, New York University School of Medicine, New York, NY, USA.
Jack Y ZhangDepartment of Pathology, New York University School of Medicine, New York, NY, USA.
Fengxia LiangDepartment of Pathology, New York University School of Medicine, New York, NY, USA.
Xin LiBasic Science and Craniofacial Biology, New York University College of Dentistry, New York, NY, USA.
Thomas A NeubertBiochemistry and Molecular Pharmacology, New York University School of Medicine, New York, NY, USA.
Laurey SteinkeDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA.
Ying ShenDepartment of Pathology, New York University School of Medicine, New York, NY, USA.
Ross BaschDepartment of Pathology, New York University School of Medicine, New York, NY, USA.
Robert SchneiderMicrobiology and Molecular Pathogenesis, New York University School of Medicine, New York, NY, USA.
David E LevyDepartment of Pathology, New York University School of Medicine, New York, NY, USA.
Peng LeeDepartment of Pathology, New York University School of Medicine, New York, NY, USA.
New York University · USHofstra University · USUniversity of Nebraska Medical Center · US

Funding

Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ADRIANA HEGUY · 1985 to 2026
$83.1M
TRAINING PROGRAM IN MOLECULAR ONCOLOGY &IMMUNOLOGYT32CA009161 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CARROLL, WILLIAM L., LEVY, DAVID E · 1985 to 2020
$13.3M
Signaling Pathway Alterations in the Racial Disparity of Prostate CancerU01CA149556 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI LEE, PENG, ZHANG, DAVID Y · 2011 to 2016
$1.9M
(PQA1) Novel epigenetic mechanism mediate metformin inhibition of prostate cancerR01CA180277 · NCI · NEW YORK UNIVERSITY · PI LI, XIN · 2013 to 2016
$1.1M
LTQ-Orbitrap Mass Spectrometer.S10RR027990 · NCRR · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI NEUBERT, THOMAS A · 2011 to 2011
$600k
Metformin as a novel chemopreventive agent for prostate cancerR03CA172894 · NCI · NEW YORK UNIVERSITY · PI LI, XIN · 2013 to 2014
$156k
NCI NIH HHS P30 CA016087NCI NIH HHS R01 CA180277NCI NIH HHS R03 CA172894NCI NIH HHS T32 CA009161NCI NIH HHS U01 CA149556NCRR NIH HHS S10 RR027990
6 · The paper itself

Abstract

TBLR1/TBL1XR1, a core component of the nuclear receptor corepressor (NCoR) complex critical for the regulation of multiple nuclear receptors, is a transcriptional coactivator of androgen receptor (AR) and functions as a tumor suppressor when expressed in the nucleus in prostate. Subcellular localization of a protein is critical for its function, and although TBLR1, as a transcriptional cofactor, has been primarily viewed as a nuclear protein, many cells also express variable levels of cytoplasmic TBLR1 and its cytoplasmic specific functions have not been studied. Prostate cancer (PCa) cells express moderately higher level of cytoplasmic TBLR1 compared to benign prostate cells. When comparing androgen-dependent (AD) to androgen-independent (AI) PCa, AI cells contain very high levels of TBLR1 cytoplasmic expression and low levels of nuclear expression. Overexpression of cytoplasmic TBLR1 in AD cells inhibits apoptosis induced by androgen deprivation therapy, either in an androgen free condition or in the presence of bicalutamide. Additionally, we identified a cytoplasmic specific isoform of TBLR1 (cvTBLR1) approximately 5 kDa lower in molecular weight, that is expressed at higher levels in AI PCa cells. By immunoprecipitation, we purified cvTBLR1 and using mass spectrometry analysis combined with N-terminal TMPP labeling and Edman degradation, we identified the cleavage site of cvTBLR1 at amino acid 89, truncating the first 88 amino acids of the N-terminus of the full length protein. Functionally, cvTBLR1 expressed in the cytoplasm reduced apoptosis in PCa cells and promoted growth, migration, and invasion. Finally, we identified a nuclear export signal sequence for TBLR1 cellular localization by deletion and site-directed mutagenesis. The roles of TBLR1 and cvTBLR1 provide novel insights into the mechanism of castration resistance and new strategies for PCa therapy.

Indexed as

ApoptosisActive Transport, Cell NucleusAndrogensCell Line, TumorCell MovementCell NucleusCell ProliferationCytoplasmDNA Mutational AnalysisDrug Resistance, NeoplasmHEK293 CellsHumansMaleMutagenesis, Site-DirectedNeoplasm InvasivenessNuclear ProteinsAndrogensAR protein, humanNuclear ProteinsReceptors, AndrogenReceptors, Cytoplasmic and NuclearRepressor ProteinsTBL1XR1 protein, humancastration resistancecvTBLR1prostate cancersubcellular localizationTBLR1

Identifiers

PMID27127173
PMCPMC5129953
OpenAlexW2342990162

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.